Recombinant hemoglobin

MYPI2025003284A0Undetermined Publication Date: 2024-05-30KANGMA (SHANGHAI) BIOTECH LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003284
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-30
Filing Date
2023-11-30
Publication Date
2024-05-30

AI Technical Summary

Technical Problem

In the existing technology, hemoglobin as a blood substitute has problems such as poor stability, large side effects, high production costs, and low yield. In particular, the instability and side effects caused by chemical modification methods are difficult to control, and site-directed mutation transformation at the DNA level is blind. sex, affecting function.

Method used

Four polypeptide chains are connected in series through connecting peptides to form a stable tetramer structure, which avoids the side effects of chemical modifications. It is produced using an in vitro cell-free protein synthesis method to simplify the process and reduce costs.

Benefits of technology

The formation of a stable tetramer structure is achieved, the output and production efficiency are improved, the side effects of chemical modification are avoided, the process is simplified and the cost is reduced, and a safe and effective blood substitute is provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025003284_DRAWING_001
    Figure PI2025003284_DRAWING_001
  • Figure PI2025003284_DRAWING_002
    Figure PI2025003284_DRAWING_002
  • Figure PI2025003284_DRAWING_003
    Figure PI2025003284_DRAWING_003
Patent Text Reader

Abstract

Provided in the present invention are a recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, a preparation method therefor, etc., so as to solve the current problems of complex processes, high production costs, low yields, etc. that are present in the process of improving the stability of the tetrameric structure of hemoglobin. The recombinant hemoglobin comprises four polypeptide chains, the polypeptide chains being two α chains and two β chains respectively, wherein the amino acid sequences of the four polypeptide chains are linked by means of a linker peptide, and the linker peptides are preferably used to sequentially link the amino acid sequences of the four polypeptide chains from the N terminus to the C terminus in any order.
Need to check novelty before this filing date? Find Prior Art

Description

Recombinant hemoglobin Technical Field

[0001] The present invention belongs to the field of biotechnology, and specifically relates to a recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, and a preparation method thereof. Background Art

[0002] Hemoglobin is a globular protein in red blood cells that carries oxygen. Its molecular weight is 64.5 kDa. Hemoglobin is composed of four polypeptide chains (subunits) bound together by non-covalent bonds. The main component of human whole blood is hemoglobin A, which has an α2β2 structure. The α chain contains 141 amino acid residues, while the β chain contains 146 amino acid residues. The α and β chains are tightly bound together to form a dimer, while two αβ dimers are loosely bound to form a hemoglobin molecule.

[0003] Blood products (blood products are defined as any therapeutic substance extracted from human blood, including whole blood, labile blood components and plasma-derived medicinal products) save millions of lives every year, significantly increase life expectancy and improve the quality of life of critically ill patients, and support complex medical and surgical procedures.

[0004] However, blood supply services worldwide face significant challenges, requiring adequate blood product supplies to meet patient needs while ensuring their quality and safety in the face of known and emerging public health threats. According to 2002 statistics, over 750 million units of blood are donated annually worldwide. However, only 43 of the World Health Organization's 191 member states test blood donors for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). Unsafe blood transfusions or injections lead to 80,000 to 160,000 HBV infections, 23,000 to 47,000 HCV infections, and 80,000 to 160,000 HIV infections annually. Furthermore, the conflict between increasing blood demand and decreasing donations, hemolysis and even death caused by mis-transfusions, the short storage life of human red blood cells, and natural disasters and wars have driven the search for alternatives to blood, including red blood cell substitutes.

[0005] Hemoglobin-based red blood cell substitutes are hemoglobin-based biopharmaceuticals with oxygen-carrying properties. They can be divided into three categories: those based on human blood, those based on animal blood, and those based on recombinant hemoglobin.

[0006] However, unmodified hemoglobin currently cannot be used as a blood substitute. One major reason is that free hemoglobin tetramers can degrade into αβ dimers and monomers, resulting in numerous side effects. To minimize these side effects, stabilizing hemoglobin tetramers is essential for its use as a blood substitute. Currently, chemical modifications, such as cross-linking, polymerization, and coupling, are commonly used to increase hemoglobin molecular weight. Furthermore, biotechnology, such as site-directed mutagenesis of the hemoglobin gene at the DNA level, can also be used to achieve these effects.

[0007] However, although chemical modification is relatively mature, it also has side effects that need to be addressed urgently. (1) Due to the different chemical reagents and methods used, and the non-specificity of the cross-linking reaction, it is difficult to control the molecular size, oxygen affinity, subunit cooperativity, stability, and toxic side effects of hemoglobin products, and the final product is a non-uniform mixture. (2) Contamination by pathogenic microorganisms still exists because the problem of blood disinfection has not been solved, and there is still a risk of spreading blood-borne diseases such as mad cow disease and acute and chronic immunogenicity to humans. (4) The instability of the final product leads to rearrangements between cross-linked hemoglobin. Because free cross-linkers are cytotoxic, whether they will fall off the cross-linked hemoglobin is a problem worthy of attention. In addition, chemical modification sometimes also has process complexity, which increases production costs and reduces production efficiency.

[0008] However, site-directed mutagenesis of the hemoglobin gene at the DNA level can sometimes lead to blindness, thus affecting the final function.

[0009] In addition, there is also the production of recombinant hemoglobin by co-expressing α and β in cells, but the yield is often very low, and after production, cross-linking chemical modification is required to increase the stability of the tetramer structure.

[0010] It can be seen that the existing technology is still insufficient in providing hemoglobin with a stable tetrameric structure.

[0011] Summary of the Invention

[0012] The present invention provides a recombinant hemoglobin, a nucleic acid encoding the recombinant hemoglobin, and a preparation method thereof, etc., to solve the problems of complex process, high production cost, large side effects, and low yield in the current efforts to improve the stability of tetrameric hemoglobin.

[0013] To this end, the present invention provides the following technical solutions:

[0014] The present invention provides a recombinant hemoglobin, characterized in that it comprises: four polypeptide chains, wherein the polypeptide chains are two α chains and two β chains, respectively, wherein the amino acid sequences of the four polypeptide chains are connected by a connecting peptide.

[0015] The recombinant hemoglobin provided by the present invention also has the following characteristics: wherein, the three connecting peptides sequentially connect the amino acid sequences of the four polypeptide chains from the N-terminus to the C-terminus in any order.

[0016] The recombinant hemoglobin provided by the present invention also has the following characteristics: wherein the number of amino acids in the connecting peptide is 1-90, 1-30, 1-35 or 1-40.

[0017] The recombinant hemoglobin provided by the present invention also has the following characteristics: the connecting peptide used to connect the two α chains is a first connecting peptide, the number of amino acids in the first connecting peptide is 1-5, preferably 1, 2 or 3, the connecting peptide used to connect the two β chains or between an α chain and a β chain is a second connecting peptide, the number of amino acids in the second connecting peptide is 5-90, 5-85, 5-30, 5-35, 5-40, 10-30, 10-35 or 10-40 amino acids.

[0018] The recombinant hemoglobin provided by the present invention also has the following feature: the amino acid of the first connecting peptide is one glycine.

[0019] The recombinant hemoglobin provided by the present invention also has the following characteristics: the second connecting peptide contains any one or more of G, S, T and A as main amino acid residues, and the number of the main amino acid residues accounts for at least greater than 50%, 60%, 70%, 80% or 90% of the total number of amino acid residues in the second connecting peptide. More preferably, the main amino acid residues contain any one or more of G and S, and the total amount thereof accounts for at least greater than 40% or greater than 45% or greater than 60% or greater than 70% or greater than 80% of the total number of amino acids in the second connecting peptide.

[0020] The recombinant hemoglobin provided by the present invention also has the following feature: the second connecting peptide contains at least a flexible unit.

[0021] The recombinant hemoglobin provided by the present invention also has the following characteristics: the second connecting peptide also contains a hydrophilic unit composed of alternating hydrophilic and hydrophobic amino acids. In this case, from the N-terminus to the C-terminus, the amino acid sequence of the second connecting peptide is: flexible unit-hydrophilic unit composed of alternating hydrophilic and hydrophobic amino acids-flexible unit.

[0022] The recombinant hemoglobin provided by the present invention also has the following characteristics: the structure of the flexible unit is (GGGGS)a, preferably, a is 1-4,

[0023] More preferably, the flexible unit is selected from:

[0024] (1)GGGGS;

[0025] (2)GGGGSGGGGS;

[0026] (3)GGGGSGGGGSGGGGSGGGGS.

[0027] The recombinant hemoglobin provided by the present invention also has the following characteristics: the structure of the affinity unit is any one or more of (RADA)b, (KLDL)c, (LK)d and (LD)f, preferably: b is 1-5, c is 1-5, d is 1-10, and f is 1-10.

[0028] More preferably, the affinity unit is selected from:

[0029] (1)RADARADARADARADA;

[0030] (2)KLDLKLDLKLDL;

[0031] (3)LKLKLKLKLKLK;

[0032] (4)LDLDLDLDLDLD.

[0033] The recombinant hemoglobin provided by the present invention also has the following feature: the amino acid sequence of the second connecting peptide is SEQ ID NO: 1-6.

[0034] The recombinant hemoglobin provided by the present invention also has the following characteristics: the connection order of the amino acid sequences of the four polypeptide chains from N-terminus to C-terminus is any one of the following: α chain-α chain-β chain-β chain, β chain-β chain-α chain-α chain, β chain-α chain-α chain-β chain, α chain-β chain-α chain-β chain, and β chain-α chain-β chain-α chain.

[0035] The recombinant hemoglobin provided by the present invention also has the following characteristics: wherein the α chain is derived from any one or species of human, pig or cattle, and the β chain is derived from any one or more of human, pig or cattle; and / or

[0036] The amino acid sequence of the α chain is any one or more of SEQ ID NOs: 7, 13, and 14, or has a sequence identity of at least 80%, 85%, 90%, 95%, 97%, or 99% to any one or more of SEQ ID NOs: 7, 13, and 14, respectively;

[0037] The amino acid sequence of the β chain is any one or more of SEQ ID NOs: 8, 15 and 16, or has a sequence homology percentage of at least 80%, 85%, 90%, 95%, 97% or 99% with any one or more of SEQ ID NOs: 8, 15 and 16, respectively.

[0038] The recombinant hemoglobin provided by the present invention also has the following characteristics, and further comprises: heme respectively bound to each of the polypeptide chains.

[0039] The present invention also provides a nucleic acid, characterized in that it comprises: nucleotides encoding the aforementioned recombinant hemoglobin.

[0040] The present invention also provides a vector, characterized in that it comprises: the aforementioned nucleic acid.

[0041] The present invention also provides a host cell, characterized in that it comprises: the aforementioned nucleic acid and / or the aforementioned vector,

[0042] Preferably, the host cell is from a prokaryotic cell or a eukaryotic cell. Further, the host cell is from a bacterium, a mammalian cell, a human cell, a plant cell, a yeast cell or an insect cell, preferably selected from Escherichia coli or a yeast cell. Further, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0043] Use of the aforementioned nucleic acid, vector or host cell of the present invention in preparing the aforementioned recombinant hemoglobin.

[0044] The present invention also provides an in vitro cell-free protein synthesis system, characterized in that it comprises: a cell extract; and an mRNA or DNA template encoding the aforementioned recombinant hemoglobin, preferably, the cell extract is an Escherichia coli extract, and the yeast cell extract is further from the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus, and Kluyveromyces dobsonii;

[0045] Furthermore, it further comprises one or more of the following components:

[0046] Amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

[0047] The present invention also provides the aforementioned in vitro cell-free synthesis method of recombinant hemoglobin, which is characterized by comprising: providing a cell-free in vitro protein synthesis system;

[0048] The mRNA or DNA template encoding the aforementioned recombinant hemoglobin is added to the cell-free protein synthesis system for an in vitro synthesis reaction to obtain the recombinant hemoglobin. Preferably, the volume ratio of the DNA template to the cell-free in vitro protein synthesis system is 1:10 to 1:50, preferably 1:20 to 1:40; most preferably 1:25 to 1:35, and particularly preferably 1:30.

[0049] The in vitro cell-free synthesis method provided by the present invention also has the following characteristics, and further comprises: adding hemoglobin to the cell-free protein synthesis system to generate recombinant hemoglobin bound to the hemoglobin. The order of adding hemoglobin is not limited and can be before or after the in vitro synthesis using the cell-free protein synthesis system.

[0050] Preferably, the added heme carries trivalent iron.

[0051] The in vitro cell-free synthesis method provided by the present invention also has the following characteristics: wherein, the cell-free in vitro protein synthesis system comprises: a cell extract;

[0052] Further,

[0053] The in vitro protein synthesis system comprises any one or more combinations of an amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, an energy supply system, polyethylene glycol, and an aqueous solvent; and / or

[0054] The cell extract is an Escherichia coli extract, and the yeast cell extract is further from the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii; or

[0055] Yeast extract accounts for 50-80% of the entire cell-free in vitro protein synthesis system.

[0056] The present invention also provides the use of the aforementioned recombinant hemoglobin as a blood substitute, and in the treatment of cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS), peripheral arterial disease (PAD) and Parkinson's disease (PD).

[0057] Functions and effects of the invention

[0058] The recombinant hemoglobin, the nucleic acid encoding the recombinant hemoglobin, and the preparation method thereof provided by the present invention have at least the following advantages:

[0059] (1) Recombinant hemoglobin connects four polypeptide chains in series in the primary structure through a connecting peptide, so that during the process of synthesizing and expressing recombinant hemoglobin in vivo or in vitro, the series-connected α chains and β chains are more likely to interact with each other to form a monomer structure with similar functions to tetrameric hemoglobin. Moreover, due to the connection in the primary structure, this structure is more stable and not easy to dissociate, and can form a stable tetramer. In addition, the series-connected α chains and β chains are in a one-to-one correspondence, which avoids the formation of other aggregated structures caused by insufficient matching of the separated α chains and β chains. The yield is higher and the production is more convenient. No additional chemical cross-linking is required, which can avoid the side effects of chemical modification, simple process and lower cost.

[0060] (2) The present invention uses the nucleic acid encoding the recombinant hemoglobin obtained by connecting four polypeptide chains in series in the primary structure as a template, and can be directly produced by in vitro cell-free synthesis, with fast production speed and low cost. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] FIG1 shows the activity test results of hemoglobin fused with EGFP (scHemoglobin-EGFP) obtained by six in vitro synthesis reactions, expressed as fluorescence values;

[0062] FIG2 is a graph showing the test results of the purification effect of six types of scHemoglobin-EGFP hemoglobin. The higher the fluorescence value, the higher the amount of protein obtained.

[0063] FIG3 is a graph showing protein bands detected by SDS-PAGE electrophoresis of the eluates purified from six types of scHemoglobin-EGFP;

[0064] FIG4 is a protein band diagram of SDS-PAGE electrophoresis detection of hemoglobin (scHemoglobin) without EGFP fusion protein obtained by six IVTT reactions and purification;

[0065] Figures 5 and 6 are graphs showing different experimental results of the effect of adding Hemin to the reaction solution for synthesizing EGFP protein (PC) in vitro;

[0066] FIG7 shows photographs of the reaction solutions of 15 scHemoglobins synthesized in vitro, after which Hemin at a final concentration of 20 μM was added, and after expression and purification, the reaction solutions were replaced with PBS solutions.

[0067] FIG8 is a graph showing the results of SDS-PAGE electrophoresis detection after normal expression purification in an in vitro synthesis reaction system without adding a DNA template but adding Hemin;

[0068] FIG9 shows the spectroscopic characteristics of hemoglobin in oxygen-carrying and oxygen-free states disclosed in Reference 1;

[0069] Figures 10-24 are spectral characteristic diagrams obtained by referring to reference 1 after the 15 scHemoglobins are bound to hemoglobin in Example 4. DETAILED DESCRIPTION

[0070] The specific embodiments of the present invention are described below with reference to the accompanying drawings. For the specific methods or materials used in the examples, those skilled in the art can make conventional replacements based on the technical ideas of the present invention and existing technologies, and are not limited to the specific description of the embodiments of the present invention.

[0071] Unless otherwise specified, the methods used in the examples are conventional methods; the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0072] The definitions of the terms used herein are intended to incorporate the definitions of the prior art generally recognized in the field of biotechnology for each term. Where appropriate, illustrations are provided. Unless otherwise limited in specific circumstances, either individually or as part of a larger group, these definitions apply to the terms used throughout this specification.

[0073] "Recombinant hemoglobin" herein refers to a hemoglobin molecule and / or variants thereof having a molecular size of at least about 65 kDa and synthesized by any standard molecular biology technique rather than isolated or purified from any animal or human source.

[0074] " Variant " herein refers to a polypeptide or polynucleotide sequence that is different from a reference polypeptide or polynucleotide sequence but retains its essential properties. Typically, a variant is very similar to the reference polypeptide or polynucleotide sequence overall and is identical in many regions.

[0075] The variant, for example, comprises the amino acid sequence of a parent polypeptide sequence having at least one conservative amino acid substitution; alternatively, the variant may comprise the amino acid sequence of a parent polypeptide sequence having at least one non-conservative amino acid substitution, in which case the non-conservative amino acid substitution preferably does not interfere with or inhibit the biological activity of the functional variant, and the non-conservative amino acid substitution may enhance the biological activity of the variant, such that the biological activity of the variant is increased compared to that of the parent polypeptide.

[0076] When used with reference to polypeptide or polynucleotide sequences, the term "percentage of sequence homology" refers to the comparison between polynucleotides and polypeptides, and is determined by comparing two optimally aligned sequences within a comparison window, wherein the portion of the polynucleotide or polypeptide sequence within the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (not comprising additions or deletions) for the optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the same nucleic acid base or amino acid residue is present in both sequences to produce the number of matching positions, dividing the number of matching positions by the total number of positions of the longer sequence in the comparison window, and multiplying the result by 100 to produce the percentage of sequence homology. Homology is evaluated using any of a variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW. In certain embodiments, protein and nucleic acid sequence homology is evaluated using the Basic Local Alignment Search Tool ("BLAST"), which is well known in the art (see, e.g., Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268; Altschul et al., 1990, J. Mol. Biol. 215:403-410; Altschul et al., 1993, Nature Genetics 3:266-272; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402).

[0077] Heme in this article refers to ferrous heme, an iron porphyrin compound, which is a cofactor of hemoglobin, as well as a cofactor of myoglobin, cytochrome, peroxidase, catalase, etc.

[0078] The "active structure" in this article refers to the prepared recombinant hemoglobin having the ability to carry oxygen and other functions, and can be prepared as or used as a blood substitute. For example, the protein before hemoglobin is bound to heme. As long as it can carry oxygen and other functions after binding to hemoglobin, it can be prepared as a blood substitute. The protein before hemoglobin is considered to have an active structure.

[0079] 1. Recombinant hemoglobin

[0080] The recombinant hemoglobin provided by the present invention comprises: four polypeptide chains, wherein the polypeptide chains are two α chains and two β chains respectively, and the amino acid sequences of the four polypeptide chains are connected by a connecting peptide, wherein the connecting peptide has no special regulations on the order and position of the amino acid sequences of the four polypeptide chains, and can be in any order and at any position: that is, the four polypeptide chains are connected together in the primary structure by one or more polypeptide connecting peptides.

[0081] In a preferred example, the three connecting peptides connect the amino acid sequences of the four polypeptide chains from N-terminus to C-terminus in any order, that is, the four polypeptide chains are connected in series, preferably in any one of the following orders: α chain-α chain-β chain-β chain, β chain-β chain-α chain-α chain, β chain-α chain-α chain-β chain, α chain-β chain-α chain-β chain and β chain-α chain-β chain-α chain: "-" is a connecting peptide, and the amino acid sequences of the three connecting peptides can be the same, or only two of them can be the same, or none of them can be different.

[0082] The number of amino acids in the linker peptide is intended to ensure that the recombinant hemoglobin forms a functional active structure and, secondly, to maintain a certain stability. Preferably, the number of amino acids in the linker peptide is 1-90, 1-30, 1-35 or 1-40.

[0083] In one example, the connecting peptide includes two:

[0084] One is used to connect the two α chains, referred to as the first connecting peptide. Preferably, the number of amino acids in the first connecting peptide is 1-5, more preferably 1, 2 or 3;

[0085] The other is used to connect two β chains or an α chain and a β chain, which is called the second connecting peptide. Preferably, the number of amino acids in the second connecting peptide is any one of 5-90, 5-85, 5-30, 5-35, 5-40, 10-30, 10-35 and 10-40.

[0086] In one example, the amino acid of the first connecting peptide is 1 glycine.

[0087] In one example, the second connecting peptide contains a majority of amino acid residues selected from the group consisting of G, S, T, and A, and the percentage of the majority of amino acid residues in the total number of amino acid residues in the second connecting peptide is at least greater than 50%, 60%, 70%, 80%, or 90%. More preferably, the majority of amino acid residues contain a majority of amino acids selected from the group consisting of G and S, and the total amount of the majority of amino acids in the second connecting peptide is at least greater than 40%, greater than 45%, greater than 60%, greater than 70%, or greater than 80%. The amino acid sequence of the second connecting peptide is, for example, SEQ ID NOs: 10-12.

[0088] In one example, the second connecting peptide contains at least a flexible unit.

[0089] In one example, the structure of the flexible unit is (GGGGS)a, preferably, a is 1-4. More preferably, the flexible unit is selected from:

[0090] (1)GGGGS;

[0091] (2)GGGGSGGGGS;

[0092] (3)GGGGSGGGGSGGGGSGGGGS.

[0093] In one example, the second connecting peptide further contains a hydrophilic unit composed of alternating hydrophilic amino acids and hydrophobic amino acids. In this case, from the N-terminus to the C-terminus, the amino acid sequence of the second connecting peptide is: flexible unit-hydrophilic unit composed of alternating hydrophilic amino acids and hydrophobic amino acids-flexible unit.

[0094] The alternation of hydrophilic amino acids and hydrophobic amino acids in this article refers to the following different situations:

[0095] (1) One hydrophilic amino acid alternates with one hydrophobic amino acid;

[0096] (2) One or more consecutive hydrophilic amino acids form a hydrophilic group, which is alternated with one or more consecutive hydrophobic amino acids form a hydrophobic group. In this case, the amino acids in each group can be the same or different. For example, within each hydrophilic group, the hydrophilic amino acids can be the same or different; the amino acid composition between different hydrophilic groups or different hydrophobic groups can be the same or different, for example;

[0097] In one example, the structure of the affinity unit is any one or more of (RADA)b, (KLDL)c, (LK)d and (LD)f, preferably: b is 1-5, c is 1-5, d is 1-10, and f is 1-10.

[0098] More preferably, the affinity unit is selected from:

[0099] (1)RADARADARADARADA;

[0100] (2)KLDLKLDLKLDL;

[0101] (3)LKLKLKLKLKLK;

[0102] (4)LDLDLDLDLDLD.

[0103] In one example, the amino acid sequence of the second connecting peptide is SEQ ID NO: 1-6.

[0104] In one example, the amino acid sequence of the α chain is SEQ ID NO: 7 or has a sequence identity of at least 80%, 85%, 90%, 95% or 99% to SEQ ID NO: 7; the amino acid sequence of the β chain is SEQ ID NO: 8 or has a sequence identity of at least 80%, 85%, 90%, 95% or 99% to SEQ ID NO: 8.

[0105] 2. The present invention also provides a nucleic acid comprising: a nucleotide sequence encoding the aforementioned recombinant hemoglobin.

[0106] The present invention also provides a vector comprising the above nucleic acid.

[0107] The present invention also provides a host cell comprising the aforementioned nucleic acid and / or the aforementioned vector, wherein the host cell is derived from a prokaryotic cell or a eukaryotic cell, and further, the cell is selected from the group consisting of one or more combinations of Escherichia coli cells, human cells, Chinese hamster cells, ovary cells, insect cells, wheat germ cells, rabbit reticulocytes, and yeast cells.

[0108] Furthermore, the host cell is selected from yeast cells, and further still, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0109] The nucleic acid, vector or host cell provided by the present invention can be used to prepare recombinant hemoglobin.

[0110] The present invention also provides an in vitro cell-free protein synthesis system, comprising: a cell extract and an mRNA or DNA template encoding the aforementioned recombinant hemoglobin.

[0111] In one example, the cell extract is an Escherichia coli extract, and the yeast cell extract is further from the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is from: Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0112] In one example, the in vitro cell-free synthesis system further comprises one or more of the following components: an amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, an energy supply system, polyethylene glycol, and an aqueous solvent.

[0113] 3. In vitro cell-free synthesis of recombinant hemoglobin, comprising:

[0114] Providing a cell-free in vitro protein synthesis system;

[0115] The mRNA or DNA template encoding the aforementioned recombinant hemoglobin is added to the cell-free protein synthesis system to perform an in vitro synthesis reaction to synthesize the single-chain polypeptide.

[0116] The volume ratio of the DNA template to the cell-free in vitro protein synthesis system is 1:10-1:50, preferably 1:20-1:40; most preferably 1:25-1:35, and particularly preferably 1:30.

[0117] In one example, a cell-free in vitro protein synthesis system includes: a cell extract.

[0118] In one example, the cell-free in vitro protein synthesis system includes any one or more combinations of an amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, an energy supply system, polyethylene glycol, and an aqueous solvent.

[0119] In one example, the cell extract is an Escherichia coli extract, and the yeast cell extract is further from the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

[0120] In one example, yeast extract comprises 50-80% of the entire cell-free in vitro protein synthesis system.

[0121] In vitro protein synthesis reaction refers to the reaction of synthesizing protein in an in vitro cell-free synthesis system, which at least includes the translation process. It includes but is not limited to IVT reaction (in vitro translation reaction), IVTT reaction (in vitro transcription and translation reaction), and IVDTT reaction (in vitro replication transcription and translation reaction). In the present invention, IVTT reaction is preferred. IVTT reaction, corresponding to IVTT system, is the process of transcribing and translating DNA into protein (Protein) in vitro. Therefore, we also refer to this type of in vitro protein synthesis system as D2P system, D-to-P system, D_to_P system, DNA-to-Protein system; the corresponding in vitro protein synthesis method is also called D2P method, D-to-P method, D_to_P method, DNA-to-Protein method.

[0122] In a preferred embodiment, in the in vitro cell-free synthesis method of the present invention, the in vitro protein synthesis system, template, plasmid, target protein, in vitro protein synthesis reaction (incubation reaction), various preparation methods, various detection methods and other technical elements of the present invention can also be independently selected from the following documents. Suitable embodiments or implementation methods include but are not limited to CN111484998A, CN106978349A, CN108535489A, CN108690139A, CN108949801A, CN108642076A, CN109022478A, CN1094234 96A, CN109423497A, CN109423509A, CN109837293A, CN109971783A, CN109988801A, CN109971775A, CN110093284A, CN110408635A, CN110408636A, CN110551745A, CN110551700A, CN110551785A, CN110819647A, CN110845622A, CN110938649A, CN110964736A, etc. Unless otherwise in conflict with the purpose of the present invention, these documents and their citations are cited in their entirety and for all purposes.

[0123] The present invention synthesizes the aforementioned recombinant hemoglobin through the aforementioned in vitro cell-free synthesis method, which has a short cycle, convenient operation, low cost, and can obtain stable hemoglobin with the aforementioned active structure.

[0124] Furthermore, the in vitro cell-free synthesis method further comprises:

[0125] Hemoglobin is added to the cell-free protein synthesis system simultaneously or after the in vitro synthesis reaction to generate recombinant hemoglobin bound to the hemoglobin. Preferably, the added hemoglobin carries trivalent iron.

[0126] The following is a detailed description of the present invention using specific experimental examples.

[0127] In the following embodiments:

[0128] (1) The IVTT reaction system is as follows: 22 mM 4-hydroxyethylpiperazineethanesulfonic acid (pH 7.4) at a final concentration, 30-150 mM potassium acetate, 1.0-5.0 mM magnesium acetate, 1.5-4 mM nucleoside triphosphate mixture (adenosine triphosphate, guanosine triphosphate, cytosine triphosphate, and uridine triphosphate), 0.08-0.24 mM amino acid mixture (glycine, alanine, valine, leucine, isoleucine, phenylalanine, proline, tryptophan, serine, tyrosine, cysteine, methionine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, and histidine), 25 mM creatine phosphate, 1.7 mM dithiothreitol, 0.27 mg / mL creatine phosphate kinase, 0.027-0.054 mg / mL T7 RNA polymerase, 1%-4% polyethylene glycol, 0.5%-2% sucrose, and finally 50-80% volume of yeast cell extract are added.

[0129] Yeast cell extract was from Kluyveromyces spp.

[0130] (2) Transformation of each target plasmid was performed as follows:

[0131] Add 1 μl of target plasmid to 20 μl of DH5α, place on ice for 30 minutes, heat shock at 42°C for 45 seconds, place on ice for 2 minutes, add 500 μl of culture medium, and culture at 37°C with shaking (200 rpm) for 1 hour. Pipette 100 μl onto an LB plate (containing antibody), incubate upside down at 37°C for 12-16 hours, and then store in a refrigerator at 4°C.

[0132] (4) Extract and amplify the transformed plasmid:

[0133] Amplification system: random primers at a final concentration of 20-30 μM, 0.05-0.15 μg / mL plasmid template, 0.5-1 mM dNTP, 2× BSA, 1× phi29 reaction buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM (NH4)2SO4, 4 mM DTT, pH 7.5).

[0134] Take 10ml amplification system as an example:

[0135] Mix 10 ml of amplification system, a plasmid with a final concentration of 4 ng / μl, and 5 μl of phi29 DNA polymerase at 0.05-0.1 mg / mL. Incubate at 37°C, 30 rpm for 2 hours, and then run on a 1% agarose gel for identification. The resulting product is used as a DNA template.

[0136] In the following examples, unless otherwise specified, the structures constructed are all from N-terminus to C-terminus.

[0137] Example 1 Expression and purification of hemoglobin fused to EGFP

[0138] Different linkers were designed to concatenate the four hemoglobin subunits, or four polypeptide chains, into a single-chain scHemoglobin. EGFP protein was fused to the C-terminus of scHemoglobin to monitor protein expression. These subunits are numbered hemo006, hemo007, hemo008, hemo009, hemo010, and hemo011. The corresponding concatenation schemes for each subunit are shown in Table 1. In this example, the amino acid sequence of the α chain is SEQ ID NO: 7, and the amino acid sequence of the β chain is SEQ ID NO: 8.

[0139] By gene synthesis, we synthesized single-chain hemoglobin genes containing different linker peptides and directly inserted them into our optimized plasmid (D2P1.08t) at the BamHI and HindIII insertion sites. Six plasmids containing the target gene fragments, hemo006-hemo011, were generated and transformed and amplified to obtain DNA templates encoding the structures shown in Table 1.

[0140] Add 15 ng / μL of DNA template to each IVTT reaction system. Mix thoroughly and incubate at 25-30°C for 3 hours. After the reaction is complete, collect the reaction solution and read the RFU fluorescence of the EGFP fusion protein using a microplate reader.

[0141] Fluorescence detection of the products of the six proteins synthesized and expressed through IVTT confirmed that all six hemoglobin fusions could be expressed normally, as shown in Figure 1.

[0142] After verifying that these scHemoglobin-EGFP fusion proteins can be expressed normally, the reaction solution after the IVTT reaction was purified to test the purification effect. 1 mL of the reaction solution after the IVTT reaction was added to nickel magnetic beads for purification, and the fluorescence values ​​of the flow-through and eluate were recorded. The purification effect is shown in Figure 2. The results show that these six scHemoglobin-EGFP design schemes can purify the target protein. In Figure 2, each protein is from left to right, in the following order: the fluorescence value of the reaction solution after the IVTT reaction (total, that is, before the addition of magnetic beads), the flow-through after binding to the magnetic beads (FT), and the final eluate (Elution).

[0143] The eluate was subjected to SDS-PAGE electrophoresis to detect protein bands. The results are shown in FIG3 , which shows that the protein size is consistent with the theoretical molecular weight.

[0144] Example 2 Expression and purification of scHemoglobin

[0145] scHemoglobin was constructed alone without EGFP fusion protein. Based on Example 1, six scHemoglobins were constructed according to the construction methods shown in Table 2:

[0146] According to the same method as Example 1, other aspects are the same as Example 1, except that EGFP was not fused. After obtaining the DNA template, the IVTT reaction system was used for reaction and purification without adding hemoglobin. The obtained protein was verified by SDS-PAGE electrophoresis as shown in Figure 4, and the results showed that scHemoglobin could be correctly expressed.

[0147] Example 3 Co-expression and purification of scHemoglobin and Hemin

[0148] Because natural hemoglobin requires heme to bind to its oxygen-carrying capacity, our synthetic hemoglobin also requires heme to function properly. However, heme binds to ferrous iron, which is highly unstable and easily oxidized to ferric iron in air. Heme can only maintain its ferrous iron stability when bound to hemoglobin. Therefore, it is currently difficult to purchase large quantities of unbound heme on the market. Heme sold on the market is generally out of stock, has a long lead time, and is expensive.

[0149] We tried to use hemin (hemoglobin chloride) as the prosthetic group of scHemoglobin. Hemin is hemoglobin with trivalent iron.

[0150] First, the possible effect of Hemin concentration in the IVTT reaction system was tested:

[0151] Different concentrations of Hemin were added to the IVTT reaction solution for EGFP protein expression synthesis to test EGFP protein expression levels and examine whether the addition of Hemin affects PC expression. Results showed that a final concentration of 3.3 μM Hemin did not affect PC IVTT expression levels, as shown in Figure 5. Subsequent testing with increasing Hemin concentrations was performed, as shown in Figure 6. A final concentration of 99 μM Hemin did not affect PC IVTT expression.

[0152] That is, the amount of hemin added has no effect on the expression of the IVTT reaction. There is no special restriction on the amount added, which is mainly higher than the expected production of hemoglobin to ensure that all expressed hemoglobin is in a hemin-bound state.

[0153] Then, the constructs shown in Tables 2 and 3 were expressed and synthesized as scHemoglobin. Hemin was added to the synthesized IVTT reaction solution at a final concentration of 20 μM for expression and purification. The results obtained for each construct were run on a gel. The gel results were consistent with the molecular weight, indicating that the target protein was obtained. In addition, after the purified protein corresponding to each construct was replaced with PBS solution, it was displayed as a blood red color (as shown in Figure 7, the first row, from left to right, are the images corresponding to the structures HM001, HM002, HM003, HM004, HM005, and HEM006 after binding to hemoglobin; the second row, from left to right, are HM007, HM008, HM009, HEM010, HM013, HM014, and HEM015; the third row, from left to right, are HEM023 and HEM024).

[0154] Because hemoglobin itself is colorless, and blood red is the color of heme, in order to exclude the possibility that free heme will be obtained in the final product after the final purification, we conducted the following control experiment (HEM-NC): During the IVTT reaction, no DNA template was added, but Hemin was added for normal expression and purification. The resulting protein eluate was also subjected to buffer exchange, and finally to PBS buffer. SDS-PAGE electrophoresis and color observation showed no scHemoglobi electrophoresis band (as shown in Figure 8), and after exchange with PBS solution, the solution was colorless and transparent, and did not show blood red. This shows that the blood red sample we obtained before is a color that can only be presented after the protein binds to Hemin.

[0155] Example 4 Oxygen carrying experiment

[0156] The oxygen carrying experiments were conducted on the proteins corresponding to the constructions in Tables 2 and 3 obtained by purification according to Example 3, as follows:

[0157] The spectroscopic properties of hemoglobin in oxygenated and oxygen-free states follow Figure 9 (Reference 1: Patel, Mira P et al. “Development and validation of an oxygen dissociation assay, a screening platform for discovering, and characterizing hemoglobin-oxygen affinity modifiers.” Drug design, development and therapy 2018, vol. 121599-1607):

[0158] As shown in Figure 9, in the oxygen-carrying state, hemoglobin has peak values ​​at 415, 541, and 577 nm. In Figure 9, it can be clearly seen that the absorbance of hemoglobin at 415 nm in the oxygen-carrying state is higher than the absorbance of hemoglobin at 430 nm in the anaerobic state; in the anaerobic state, hemoglobin has peak values ​​at 430 nm and 555 nm. In Figure 9, it can be clearly seen that the absorbance of hemoglobin at 430 nm in the anaerobic state is higher than the absorbance of hemoglobin at 430 nm in the oxygen-carrying state.

[0159] The conversion of hemoglobin from an oxygen-carrying state to an anaerobic state is catalyzed by sodium dithionite: after sodium dithionite is added to the oxygen-carrying hemoglobin, the hemoglobin is reduced and simultaneously loses oxygen, becoming deoxygenated, resulting in a transformation in its spectral properties. Based on this, spectral detection was performed on the heme-bound proteins corresponding to the constructions in Tables 2 and 3 obtained according to Example 3. The results are shown in Figures 10-24:

[0160] As can be seen from Figures 10-24, the optical properties of the 15 hemoglobin-bound proteins obtained in Example 3 are consistent with the schematic diagram of Figure 9 in spectral detection, which confirms that the present invention can synthesize functional hemoglobin by connecting the amino acid sequences of the four polypeptide chains through connecting peptides.

[0161] Example 5 Stability Test

[0162] Protein stability is determined by its Tm value, which is measured using the Uncle Protein Stability Analyzer from Unchained.

[0163] Intrinsic fluorescence in proteins originates from amino acids containing benzene rings (tryptophan, tyrosine, and phenylalanine). When excited by ultraviolet light, they emit absorbed photons (i.e., fluorescence). The intensity of the emitted fluorescence varies depending on the environment in which these aromatic amino acids reside within the protein. Therefore, the changing trend of intrinsic fluorescence can be used to indicate conformational changes in the protein's tertiary structure, thereby analyzing protein conformational stability.

[0164] By monitoring the changes in fluorescence during heating, a thermal denaturation curve can be generated, which describes one or more phase transitions during protein denaturation. The midpoint of this transition (Tm) can be used to describe the stability of the protein. The higher the Tm, the more stable the protein.

[0165] The Tm value of the same hemoglobin used in the oxygen carrying experiment in Example 4 was tested. The average Tm value was not much different from the Tm value of the bovine hemoglobin in the control group, indicating that the stability of the modified hemoglobin maintained the level of the original protein.

[0166] The sequences mentioned above are summarized in Table 4.

Claims

1. A recombinant hemoglobin, characterized in that include: Four polypeptide chains, two α chains and two β chains, Wherein, the amino acid sequences of the four polypeptide chains are connected via a connecting peptide.

2. The recombinant hemoglobin according to claim 1, characterized in that: in, The three connecting peptides sequentially connect the amino acid sequences of the four polypeptide chains from N-terminus to C-terminus in any order.

3. The recombinant hemoglobin according to claim 1 or 2, characterized in that: in, The number of amino acids in the connecting peptide is 1-90, 1-30, 1-35 or 1-40.

4. The recombinant hemoglobin according to claim 3, characterized in that: The connecting peptide used to connect the two α chains is the first connecting peptide, and the number of amino acids in the first connecting peptide is 1-5, preferably 1, 2 or 3. The connecting peptide used to connect two β chains or one α chain and one β chain is a second connecting peptide, and the number of amino acids in the second connecting peptide is 5-90, 5-85, 5-30, 5-35, 5-40, 10-30, 10-35 or 10-40 amino acids.

5. The recombinant hemoglobin according to claim 4, characterized in that: The amino acid of the first connecting peptide is 1 glycine.

6. The recombinant hemoglobin according to claim 4 or 5, characterized in that: The second connecting peptide contains any one or more of G, S, T and A. Amino acid residues, and the number of the main amino acid residues accounts for at least greater than 50%, 60%, 70%, 80% or 90% of the total number of amino acid residues in the second connection. More preferably, the main amino acid residues contain any one or more amino acids of G and S, and the total amount thereof accounts for at least greater than 40% or greater than 45% or greater than 60% or greater than 70% or greater than 80% of the total number of amino acids in the second connection.

7. The recombinant hemoglobin according to claim 4 or 5, characterized in that: The second connecting peptide contains at least a flexible unit.

8. The recombinant hemoglobin according to claim 7, characterized in that: The second connecting peptide further contains a hydrophilic unit composed of alternating hydrophilic and hydrophobic amino acids. In this case, from the N-terminus to the C-terminus, the amino acid sequence of the second connecting peptide is: flexible unit-hydrophilic unit composed of alternating hydrophilic and hydrophobic amino acids-flexible unit.

9. The recombinant hemoglobin according to claim 7 or 8, characterized in that: The structure of the flexible unit is (GGGGS)a, Preferably, a is 1-4, More preferably, the flexible unit is selected from: (1) GGGGS; (2)GGGGSGGGGS; (3)GGGGSGGGGSGGGGSGGGGS.

10. The recombinant hemoglobin according to claim 8 or 9, characterized in that: The structure of the affinity unit is any one or more of (RADA)b, (KLDL)c, (LK)d and (LD)f. Preferably: b is 1-5, c is 1-5, d is 1-10, f is 1-10, More preferably, the affinity unit is selected from: (1)RADARADARADARADA; (2)KLDLKLDLKLDL; (3)LKLKLKLKLKLK; (4)LDLDLDLDLDLD.

11. The recombinant hemoglobin according to any one of claims 4, 5 and 7-1, characterized in that: The amino acid sequence of the second connecting peptide is SEQ ID NO: 1-6.

12. The recombinant hemoglobin according to any one of claims 1 to 11, characterized in that: The connection order of the amino acid sequences of the four polypeptide chains from N-terminus to C-terminus is any one of the following: α chain-α chain-β chain-β chain, β chain-β chain-α chain-α chain, β chain-α chain-α chain-β chain, α chain-β chain-α chain-β chain and β chain-α chain-β chain-α chain.

13. The recombinant hemoglobin according to any one of claims 1 to 12, characterized in that: in, The α chain is derived from any one or species of human, pig or cattle, and the β chain is derived from any one or more of human, pig or cattle; and / or The amino acid sequence of the α chain is any one or more of SEQ ID NOs: 7, 13, and 14, or has a sequence identity of at least 80%, 85%, 90%, 95%, 97%, or 99% to any one or more of SEQ ID NOs: 7, 13, and 14, respectively; The amino acid sequence of the β chain is any one or more of SEQ ID NOs: 8, 15 and 16, or has a sequence homology percentage of at least 80%, 85%, 90%, 95%, 97% or 99% with any one or more of SEQ ID NOs: 8, 15 and 16, respectively.

14. The recombinant hemoglobin according to any one of claims 1 to 11, characterized in that Also includes: Heme is separately bound to each of the polypeptide chains.

15. A nucleic acid, characterized in that include: A nucleotide encoding the recombinant hemoglobin according to any one of claims 1 to 14.

16. A carrier, characterized in that include: The nucleic acid of claim 15.

17. A host cell, characterized in that include: The nucleic acid according to claim 15 and / or the vector according to claim 16, Preferably, the host cell is derived from a prokaryotic cell or a eukaryotic cell. Furthermore, the host cell is derived from bacteria, mammalian cells, human cells, The plant cell, yeast cell or insect cell is preferably selected from Escherichia coli or yeast cell. Furthermore, the yeast cell is selected from: a combination of one or more of Saccharomyces cerevisiae and Kluyveromyces yeast. In another preferred embodiment, the Kluyveromyces yeast is selected from: a combination of one or more of Kluyveromyces lactis, Kluyveromyces marxianus and Kluyveromyces dobsonii.

18. Use of the nucleic acid according to claim 15, the vector according to claim 16 or the host cell according to claim 17 in preparing the recombinant hemoglobin according to any one of claims 1 to 14.

19. An in vitro cell-free protein synthesis system, characterized in that: include: cell extracts; as well as The mRNA or DNA template encoding the recombinant hemoglobin according to any one of claims 1 to 14, preferably, the cell extract is an Escherichia coli extract, the yeast cell extract is further from the following group: any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus, and Kluyveromyces dobsonii; Furthermore, it further comprises one or more of the following components: Amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, energy supply system, polyethylene glycol and aqueous solvent.

20. The in vitro cell-free synthesis method of recombinant hemoglobin according to any one of claims 1 to 14, characterized in that: include: Providing a cell-free in vitro protein synthesis system; The recombinant hemoglobin is obtained by adding an mRNA or DNA template encoding the recombinant hemoglobin according to any one of claims 1 to 14 to the cell-free protein synthesis system for an in vitro synthesis reaction. Preferably, the volume ratio of the DNA template to the cell-free in vitro protein synthesis system is 1:10 to 1:50, preferably 1:20 to 1:40; most preferably 1:25 to 1:35, and particularly preferably 1:

30.

21. The in vitro cell-free synthesis method according to claim 20, characterized in that: Also includes: Heme is added to the cell-free protein synthesis system to generate recombinant hemoglobin bound to the heme. Preferably, the added heme is ferric.

22. The in vitro cell-free synthesis method according to claim 20 or 21, Its characteristics are: Wherein, the cell-free in vitro protein synthesis system comprises: cell extract; Furthermore, The cell-free in vitro protein synthesis system comprises any one or more combinations of an amino acid mixture, dNTPs, RNA polymerase, DNA polymerase, an energy supply system, polyethylene glycol, and an aqueous solvent; and / or The cell extract is an Escherichia coli extract, the yeast cell extract, In one step, the yeast cell extract is from the group consisting of any one or more combinations of Saccharomyces cerevisiae, Pichia pastoris, and Kluyveromyces; preferably, the yeast cell extract is from Kluyveromyces, more preferably any one or more combinations of Kluyveromyces lactis, Kluyveromyces marxianus, and Kluyveromyces dobsonii; or Yeast extract accounts for 50-80% of the entire cell-free in vitro protein synthesis system.

23. Use of the recombinant hemoglobin according to any one of claims 1 to 14 as a blood substitute, and in the treatment of cancer, stroke, hemorrhagic shock, acute mountain sickness (AMS), peripheral arterial disease (PAD) and Parkinson's disease (PD).